Research
Hormonal
Women on hormone therapy (HT) had a higher total body weight loss percentage (TBWL%) at 3, 6, 9, and 12 months compared to women not on HT.
Practitioners may consider hormone therapy as a factor in weight loss strategies for postmenopausal women.
StrongSupportsmedium confidence
Women on HT had a higher TBWL% at 3, 6, 9, and 12 months: 7 ± 3% vs 5 ± 4%, P = 0.01; 13 ± 6% vs 9 ± 5%, P = 0.01; 15 ± 6% vs 10 ± 6%, P = 0.02; and 16 ± 6% vs 12 ± 8%, P = 0.04; respectively.
Why this rating
The study is a retrospective cohort study with clear statistical significance.
Source
Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use
Maria D. Hurtado et al. · Menopause The Journal of The North American Menopause Society · 2024
DOI 10.1097/gme.0000000000002310
cohort · n=106Cited 26×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →